AbbVie (NYSE: ABBV) announced results from two Phase 2 clinical trials evaluating its investigational selective JAK1 inhibitor, ABT-494, in patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA

AbbVie to Advance Once-Daily ABT-494 to Phase 3 in Rheumatoid Arthritis by Year-EndSeptember 25, 2015 7:13 AM AbbVie's ABT-494 Meets Primary Endpoint in Two Phase 2 Studies in Rheumatoid ArthritisSeptember 25, 2015 7:12 AM